On direct compression lines for 300 mg zidovudine immediate-release tablets, the API is blended with microcrystalline cellulose, pregelatinized starch, sodium starch glycolate, and magnesium stearate in bin blenders filled to 70–80% of working volume. Segregation potential is assessed by discharging the blender and sampling at 10 designated locations; assay results are compared using USP <905> uniformity of dosage units, with acceptance values above 15.0 triggering a batch rejection under 21 CFR 211.110. Rotary tablet presses fitted with 9.5 mm round standard concave tooling are limited to 40–60 rpm unless the formulation demonstrates a compressibility index below 15% by USP <1174>. When annular shear cell testing returns a flow function coefficient below 4.0, die filling becomes erratic and mass RSD exceeds 2.0% at production speed, so the batch is diverted to roller compaction or wet granulation. Dissolution in 0.1 N HCl at 37 °C per USP <711> using Apparatus 2 at 50 rpm is sensitive to sodium starch glycolate content; levels below 2.0 wt% can delay release, while levels above 6.0 wt% increase hygroscopic expansion after storage at 40 °C/75% RH and contribute to capping on ejection. Tablet hardness is maintained between 60 N and 100 N by limiting magnesium stearate lubrication to not more than 5 minutes after the main blend is formed, because extended mixing beyond 15 minutes reduces tensile strength and extends disintegration beyond the limit in USP <701>.

What Moisture Envelope Prevents Lamination During High-Speed Compression of Zidovudine Granules?

Wet granulation is selected when the API particle size distribution contains D90 above 150 µm or bulk density below 0.35 g/mL, because direct compression cannot maintain weight RSD below 1.5% at press speeds above 50 rpm. In high-shear granulator bowls with 25–65 L working capacity, povidone K30 solution at 3–5 wt% is sprayed at 20–30 g/min per kg of dry mix. After impeller and chopper operation for 2–4 minutes, the wet mass is discharged through a 4.0 mm screen and dried in a fluid-bed dryer to loss on drying between 1.5% and 2.5% w/w at 105 °C for 5 minutes. Dried granules are milled through a 0.8 mm screen using an oscillating granulator or a cone mill with 1000 µm rasp at 1200 rpm. The drying endpoint is the critical threshold: residual moisture below 1.0% w/w generates brittle granules with high fines content, raises ejection force above 400 N, and promotes lamination; moisture above 3.0% w/w causes picking on punch faces and lowers tablet hardness. Granule D50 is controlled between 100 µm and 180 µm by sieve analysis per USP <786>, and fines passing 75 µm are held below 25% by weight. Tablet presses operate with pre-compression force 2–4 kN and main compression force 10–18 kN, with ejection force monitored continuously because an upward trend above 250 N over a 6-hour run indicates insufficient lubrication or tooling damage. Chromium nitride-coated tooling is used to reduce picking, and dissolution testing per USP <711> in 0.1 N HCl with Apparatus 2 at 50 rpm verifies release of not less than 80% at 30 minutes where the applicable monograph acceptance table applies.

In hard gelatin capsule filling suites, zidovudine 100 mg formulations are filled on tamping pin or dosator machines with powder bed height maintained between 25 mm and 40 mm. Because the API can become cohesive at relative humidity above 60%, suite conditions are held at 20–25 °C and 35–45% RH. The powder blend contains sodium starch glycolate at 4.0–6.0 wt% and magnesium stearate at 0.5–1.0 wt%; capsule weight variation is tested per USP <905> with an acceptance value not more than 15.0, and content uniformity is assessed by the same chapter. Hard gelatin shell moisture is controlled between 13% and 16% w/w: below 13% w/w shell brittleness increases splitting on high-speed filling machines, while above 16% w/w dimpling and gelatin cross-linking can appear during storage. Dissolution of zidovudine capsules in 0.1 N HCl per USP <711> is generally faster than tablets when superdisintegrant is distributed in the powder bed rather than granulated, but segregation risk rises when fill weight is below 200 mg. On dosator machines, powder plug length is set at 8–12 mm and compression force at 10–30 N, depending on capsule size and fill weight; weight RSD above 2.0% triggers a reduction in machine speed or adjustment of the powder feeder agitator speed. Empty capsule shells are dedusted and inspected, and filled capsules are metal-checked before packaging.

Buffered Oral Solution pH Drift During 24-Month Storage

Zidovudine oral solution 10 mg/mL is compounded with sucrose or glycerin, citric acid and sodium citrate buffers, and sodium benzoate at 0.1% w/v as preservative. The solution pH is adjusted to 3.0–4.0 because zidovudine solubility and chemical stability are pH-dependent; outside this range, precipitation or accelerated degradation can occur. Release and stability specifications use a tighter pH interval of 3.3–3.8 under USP <791> to limit pH drift during 24-month storage at 25 °C/60% RH per ICH Q1A(R2). Sodium benzoate is retained because the azide group in zidovudine is incompatible with strong oxidizing preservatives; nitrogen purging reduces dissolved oxygen below 0.5 mg/L before filling to minimize oxidative degradation. Filling lines use volumetric piston fillers with fill volume 100 mL ± 2.0 mL and in-line checkweighing, while closure torque is verified after capping. For reconstitutable granules intended for pediatric dosing, zidovudine is wet-granulated with sucrose or mannitol and flavored; residual moisture is dried below 1.0% w/w to prevent clumping and microbial growth. After reconstitution with 100 mL of purified water at 25 °C, the suspension is tested for content uniformity per USP <905> and preservative efficacy per USP <51> if the preparation is multi-dose. The reconstituted suspension is assigned a use period based on antimicrobial effectiveness and chemical stability data.

When Pre-Filtration Bioburden Exceeds 10 CFU/100 mL in Zidovudine Injection

For the 10 mg/mL zidovudine injection presented in single-use vials, aseptic processing is preferred over terminal steam sterilization because published data for terminal sterilization of the azide-containing solution at 121 °C is limited and thermal degradation cannot be excluded. The drug substance is dissolved in Water for Injection, pH is adjusted with hydrochloric acid or sodium hydroxide, and the solution is passed through a 0.22 µm sterilizing-grade membrane under 21 CFR 211.113. Pre-filtration bioburden is monitored per 21 CFR 211.110 and controlled to not more than 10 CFU/100 mL before the final sterilizing filter; if this limit is exceeded, the bulk solution is reprocessed only after a documented deviation and additional filtration validation. Filter integrity is tested by bubble point or diffusion per ASTM F838-20 before and after filling. The filling operation is conducted under Grade A conditions with nitrogen headspace to maintain residual oxygen below 0.5% v/v. Subvisible particulate matter is controlled per USP <788>: for containers meeting the large-volume parenteral threshold, not more than 6000 particles per container at ≥10 µm and not more than 600 per container at ≥25 µm; for small-volume vials, the harmonized limits apply. Visible particulates are inspected per USP <790> under controlled lighting. Diluted infusions at 2 mg/mL in 0.9% sodium chloride or 5% dextrose are typically assigned stability of 24 hours at 25 °C and 48 hours at 2–8 °C based on the reference product label, but each site must verify these limits with in-house stability data.

Fixed-dose combination tablets containing zidovudine 300 mg and lamivudine 150 mg are produced as monolayer blends or bilayer structures on rotary presses equipped with two feeding systems and independent pre-compression stations. When monolayer blends are used, both APIs are milled to D90 below 150 µm to prevent demixing during bin blender discharge; blend uniformity is tested by sampling 10 locations after 10, 20, and 30 minutes of blending, with acceptance value not more than 15.0 per USP <905> for each API. Dissolution testing per USP <711> uses 0.1 N HCl for zidovudine, while lamivudine may require separate conditions if the applicable monograph specifies a different medium. Bilayer tablet compression is more sensitive to interface lamination because the first layer must bond to the second without densification. First-layer pre-compression force is set to 3–6 kN, first-layer main compression to 8–15 kN, and second-layer main compression to 18–25 kN; press speed is limited to 30–50 rpm to reduce air entrapment at the interface. Tablet hardness is measured across the diameter and interface, with hardness variation above 15% RSD triggering rejection. The table below summarizes monolayer and bilayer processing limits.

Dispersible tablet presentations of zidovudine for pediatric antiretroviral programs are produced with tablet hardness 30–50 N and disintegration time in water at 25 °C of less than 60 seconds per USP <701>. The low hardness and fast disintegration are achieved by using microcrystalline cellulose with low moisture content and croscarmellose sodium at 2.0–4.0 wt%; higher levels increase water uptake but reduce tablet hardness below the handling threshold. The tablets are dispersed in 10 mL of water before administration, and the resulting dispersion is tested for uniformity of dose by sampling at the start, middle, and end of a 30-minute administration window. Because these tablets are intended for pediatric administration, bitterness masking is controlled by film coating or taste-masked granulation; coating suspension solids are maintained at 10–15% w/w and spray rate is adjusted to avoid overwetting. Stability under Zone IVb conditions at 30 °C/75% RH is evaluated per ICH Q1A(R2), and desiccant loading in the container is based on moisture sorption isotherms of the tablet formula.